Articles By Jack Cush, MD
CMS Final Rule on Prior Authorization Reforms
Prior authorizations and paperwork are killing medical providers; the good news is that a new CMS rule may lessen the burden. The Centers for Medicare & Medicaid Services (CMS) has announced that they have finalized the CMS Interoperability and Prior Authorization Final Rule, designed to improve prior authorization processes and reduce burden on patients, providers, and payers, with a resultant $15 billion of estimated savings over ten years.
Read Article
Tic-Borne Disorders Causing Chronic Arthritis?
Findings from a population based cross-sectional study suggests that while up to 20% of patients have antibodies to tick-borne exposures, only a minority reported musculoskeletal symptoms.
Read Article
2023 EULAR Non-pharmacological Management of Hip and Knee Osteoarthritis: 2023 update
EULAR has published the 2023 updated recommendations for the optimal non-pharmacological management of hip and knee osteoarthritis (OA).
Read Article
Sodium Channels, Carbemazepine and Osteoarthritis Progression
A study published in Nature suggests that therapies affecting sodium channels could be employed to treat osteoarthritis.
Read Article
2023 Rheumatology Year in Review
Dr. Jack Cush reviews highlights, advances and hot topics in rheumatology from 2023 and the RheumNow website. 2023 was a year of growth and new horizons while returning to operational and practice standards (in care and education) established before the pandemic.
Read Article
Increased CV Comorbidity in Dermatomyositis
A cohort study suggest that patients with dermatomyositis (DM) are at an increased risk for multiple comorbidities, including chronic kidney and cardiovascular disease,
Read Article
Drug-Induced Dermatomyositis
A JAMA Dermatology systematic review of drug-induced dermatomyositis (DM) found the most commonly implicated agents include hydroxyurea, immune checkpoint inhibitors, statins and lipid-lowering agents, penicillamine, and tumor necrosis factor inhibitors.
Read Article
2023 Rheumatology Year in Review
Here is my top 10 list (in no particular order) of 2023 advances, game-changers, and developments that changed, or will soon change, rheumatologic practices.
Read Article
2023 In Memoriam
In 2023, too many of our rheumatology colleagues passed away. Here is an incomplete list of our revered fellow practitioners, mentors, role-models, and researchers.
Read Article
Florida Approves Import of Drugs from Canada
Last Friday, the Food and Drug Administration (FDA) approved Florida’s plan to import certain prescription drugs directly from Canada. Florida is the first time a state to undertake this pathway to save money.
Read Article
